Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain

Bernatoniene, Jurga; Sciupokas, Arunas; Kopustinskiene, Dalia Marija; Petrikonis, Kestutis

doi:10.3390/pharmaceutics15071799

Open AccessReview

Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain

by

Jurga Bernatoniene

^1,2,*

,

Arunas Sciupokas

^3,4,

Dalia Marija Kopustinskiene

²

and

Kestutis Petrikonis

⁴

¹

Department of Drug Technology and Social Pharmacy, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania

²

Institute of Pharmaceutical Technologies, Faculty of Pharmacy, Medical Academy, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50161 Kaunas, Lithuania

³

Pain Clinic, Lithuanian University of Health Sciences Hospital Kauno Klinikos, Eivenių Str. 2, LT-50009 Kaunas, Lithuania

⁴

Department of Neurology, Lithuanian University of Health Sciences, Eivenių Str. 2, LT-50009 Kaunas, Lithuania

^*

Author to whom correspondence should be addressed.

Pharmaceutics 2023, 15(7), 1799; https://doi.org/10.3390/pharmaceutics15071799

Submission received: 26 May 2023 / Revised: 19 June 2023 / Accepted: 20 June 2023 / Published: 23 June 2023

(This article belongs to the Special Issue Exploring Innovative Drug Delivery Systems and Pharmacological Targets for Pain and Inflammation Relief)

Download

Browse Figures

Versions Notes

Abstract

Neuropathic pain is a debilitating condition characterized by abnormal signaling within the nervous system, resulting in persistent and often intense sensations of pain. It can arise from various causes, including traumatic nerve injury, neuropathy, and certain diseases. We present an overview of current and emerging pharmacotherapies for neuropathic pain, focusing on novel drug targets and potential therapeutic agents. Current pharmacotherapies, including tricyclic antidepressants, gabapentinoids, and serotonin norepinephrine re-uptake inhibitors, are discussed, as are emerging treatments, such as ambroxol, cannabidiol, and N-acetyl-L-cysteine. Additionally, the article highlights the need for further research in this field to identify new targets and develop more effective and targeted therapies for neuropathic pain management.

Keywords: neuropathic pain; therapy; tricyclic antidepressants; gabapentinoids; ambroxol; cannabidiol; N-acetyl-L-cysteine

Share and Cite

MDPI and ACS Style

Bernatoniene, J.; Sciupokas, A.; Kopustinskiene, D.M.; Petrikonis, K. Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain. Pharmaceutics 2023, 15, 1799. https://doi.org/10.3390/pharmaceutics15071799

AMA Style

Bernatoniene J, Sciupokas A, Kopustinskiene DM, Petrikonis K. Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain. Pharmaceutics. 2023; 15(7):1799. https://doi.org/10.3390/pharmaceutics15071799

Chicago/Turabian Style

Bernatoniene, Jurga, Arunas Sciupokas, Dalia Marija Kopustinskiene, and Kestutis Petrikonis. 2023. "Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain" Pharmaceutics 15, no. 7: 1799. https://doi.org/10.3390/pharmaceutics15071799

APA Style

Bernatoniene, J., Sciupokas, A., Kopustinskiene, D. M., & Petrikonis, K. (2023). Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain. Pharmaceutics, 15(7), 1799. https://doi.org/10.3390/pharmaceutics15071799

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Novel Drug Targets and Emerging Pharmacotherapies in Neuropathic Pain

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI